Phase II study of antineoplastons A10 and AS2-1 in patients with adenocarcinoma of the lung
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Antineoplaston-A10 (Primary) ; Antineoplaston-AS2-1 (Primary)
- Indications Lung cancer
- Focus Therapeutic Use
- 26 Jul 2017 Status changed from active, no longer recruiting to discontinued due to Slow accrual.
- 03 Sep 2005 New trial record.